Compare Abbott Laboratories (ABT) vs Bank of Nova Scotia (BNS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Bank of Nova Scotia — how do they compare? Abbott Laboratories trades at $95.23 (market cap $166.94B), while Bank of Nova Scotia trades at $84.99 (market cap $105.63B). The key difference: Abbott Laboratories is the larger of the two by market cap, and Bank of Nova Scotia pays the higher dividend (3.83%). Which is the better fit depends on your goals.
| ABT | BNS | |
|---|---|---|
Market Cap | $166.94B | $105.63B |
Sector | Health | Financials |
52-Week High | $136.62 | $87.35 |
52-Week Low | $82.57 | $54.50 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | 3.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
BNS trades at $86.20, up 0.94% today, with strong technical momentum showing bullish moving averages and resistance near $88. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS expected at $1.51, while revenue grew to $37.10B in 2025. Recent news highlights dividend increases and strategic acquisitions like MapleMark Bank, reinforcing growth prospects in global markets.
Outlook remains positive with analyst consensus favoring Buy ratings (52.63%), though valuation multiples like P/E of 17.05 warrant monitoring. Key risks include economic sensitivity and debt levels, but robust cash flow and dividend yield support income-focused investors. Upside depends on execution of growth initiatives and sustained earnings momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Bank of Nova Scotia
Bank of Nova Scotia is a global financial services provider. The bank has five business segments: Canadian banking, international banking, global wealth management, global banking and markets, and other. It offers a range of advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. The bank's international operations span numerous countries and are more concentrated in Central and South America.
Read more on BNS →
